Floatz logo

ly03010

Schizophrenia Spectrum and Other Psychotic Disorders

Luye Pharma Group Ltd.Phase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Schizophrenia Spectrum and Other Psychotic Disorders cohort.

Asset / SponsorPhaseRating
Risperdal
Réseau de Santé Vitalité Health Network
Phase 4BB
Metformin
The University of Hong Kong
Phase 2/3B
UMBELLATINE
The University of Hong Kong
Phase 2/3B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Region Örebro County
Phase 2B
Olanzapine
University Hospital, Strasbourg, France
Phase 2CCC
PALIPERIDONE PALMITATE , (R)-
Réseau de Santé Vitalité Health Network
D
Paliperidone Palmitate 3-Month Formulation
Réseau de Santé Vitalité Health Network
D

Same molecule, other indications

ly03010 is also rated in:

Antipsychotic AgentsDormant
CCC
Indicative ·
52 / 100
View asset →
mood disorderDormant
CCC
Indicative ·
52 / 100
View asset →
Physiological Effects of DrugsDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →